In clinical trials, researchers found that miR-107 and miR-206 may be regulated by Aβ precursor protein lyase 1 (BACE1) which reduces the abnormal accumulation of Aβ and improves the learning and memory ability of AD patients, and miRNAs can be used as a reliable biomarker for the diagnosis of AD (NCT01819545, NCT02129452) [204–206]. Here, BACE1 is linked to Alzheimer disease.